E It would be useful to have a standard UK pre and post questionnaire for We agree that the introduction of standardised patients to standardise recording (8.1.2.3) questionnaires would have clear potential advantages for clinical care and/ or research. We now discuss this further in Section 10, ‘further research’. F It may useful to consider measuring the micriobiol strains of donors to monitor We agree of the importance of this, and this is now discussed the impact of combinations of specific microbial strains to understand the in more detail in Section 10, ‘further research’. undefined nature of faecal preparations G The lack of universal definitions of cures (8.1.2.4) is likely to hamper future We agree with this comment. Section 10, ‘further research’ studies has been amended accordingly. Furthermore, we expect that the attention generated by this guideline will highlight this inadequacy. H With the introduction of the clinical term SNOMECT across primary care in We agree that there should be specific procedure codes for 2018 and secondary care in 2020 it is important to record faecal microbiota FMT (according to route of administration), so that this can be transplant so that long term sequaelae can be measured and patients can be accurately recorded in the patient’s medical record. This potentially contacted in the future. would also lay the foundation for a future HRG code and tariff for the procedure which is not currently funded by CCGs. Members of the working group are in discussion with NHS England about this. Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to Healthcare Infection Society The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential Consultation – indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
E It would be useful to have a standard UK pre and post questionnaire for patients to standardise recording (8.1.2.3) We agree that the introduction of standardised questionnaires would have clear potential advantages for clinical care and/ or research. We now discuss this further in Section 10, ‘further research’. F It may useful to consider measuring the micriobiol strains of donors to monitor the impact of combinations of specific microbial strains to understand the undefined nature of faecal preparations We agree of the importance of this, and this is now discussed in more detail in Section 10, ‘further research’. G The lack of universal definitions of cures (8.1.2.4) is likely to hamper future studies We agree with this comment. Section 10, ‘further research’ has been amended accordingly. Furthermore, we expect that the attention generated by this guideline will highlight this inadequacy. H With the introduction of the clinical term SNOMECT across primary care in 2018 and secondary care in 2020 it is important to record faecal microbiota transplant so that long term sequaelae can be measured and patients can be potentially contacted in the future. We agree that there should be specific procedure codes for FMT (according to route of administration), so that this can be accurately recorded in the patient’s medical record. This would also lay the foundation for a future HRG code and tariff for the procedure which is not currently funded by CCGs. Members of the working group are in discussion with NHS England about this. Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to Healthcare Infection Society Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
fmt-appendices-a-e.docx